Novartis, one of the most influential drug makers in the market, has landed itself in fresh trouble after revealing that an executive sold its share days before the Zolgensma drug data manipulation came out in public.
What happened at Novartis?
The unknown Novartis executive, as revealed by the company, sold share worth 925,400 Swiss Francs about three weeks before the US Food and Drug Administration (FDA) said that the data from Zolgensma gene therapy had been manipulated.
The company has previously announced the ouster of two brother scientists holding top positions in a subsidiary company that developed Zolgensma. It is unclear if either of the two brothers had sold their shares in the company. The company noted that they had not been involved in any of their projects since May when the drug was accepted by the FDA.
The news of the stock sale was first shared by SonntagsZeitung this Sunday. The company had included the sale in a Swiss stock exchange filing on July 19. According to the filing, a member of the executive committee or board of directors of Novartis sold their stock. A company spokesperson explained, “As is usual in such cases, the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”
No wrongdoing in the sale
The chain of events following the stock sale looks odd prima facie even though Novartis spokesperson suggests that the person who sold the shares was not aware of the drug manipulation case. However, it must be noted that the sale was made on July 19 and Novartis informed the FDA about manipulation much before that. The FDA noted that after it approved the drug in May, the company came to them with news of manipulated data in June.
Only the public announcement of the scandal was made on August 6, following which the company’s shares tanked by 3%. According to the regulator, the company was aware of the early testing data manipulation to support the drug for about two months before the approval. It could now face civil or criminal penalties for the same.
The data used to compare the early version of the drug against its later versions. Note that the company had changed the manufacturing process of the drug because of which the data comparison was crucial. The FDA hasn’t put Zolgensma off the shelves as it believes that the comparison doesn’t impact the safety of the drugs.
Trusted & Regulated Stock & CFD Brokers
What we like
- 0% Fees on Stocks
- 5000+ Stocks, ETFs and other Markets
- Accepts Paypal Deposits
Min Deposit
$200
Charge per Trade
Zero Commission on real stocks
64 traders signed up today
Visit Now67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Available Assets
- Total Number of Stocks & Shares5000+
- US Stocks
- German Stocks
- UK Stocks
- European
- ETF Stocks
- IPO
- Funds
- Bonds
- Options
- Futures
- CFDs
- Crypto
Charge per Trade
- FTSE 100 Zero Commission
- NASDAQ Zero Commission
- DAX Zero Commission
- Facebook Zero Commission
- Alphabet Zero Commission
- Tesla Zero Commission
- Apple Zero Commission
- Microsoft Zero Commission
Deposit Method
- Wire Transfer
- Credit Cards
- Bank Account
- Paypall
- Skrill
- Neteller
What we like
- Sign up today and get $5 free
- Fractals Available
- Paypal Available
Min Deposit
$0
Charge per Trade
$1 to $9 PCM
Visit Now
Investing in financial markets carries risk, you have the potential to lose your total investment.
Available Assets
- Total Number of Shares999
- US Stocks
- German Stocks
- UK Stocks
- European Stocks
- EFTs
- IPOs
- Funds
- Bonds
- Options
- Futures
- CFDs
- Crypto
Charge per Trade
- FTSE 100 $1 - $9 per month
- NASDAQ $1 - $9 per month
- DAX $1 - $9 per month
- Facebook $1 - $9 per month
- Alphabet $1 - $9 per month
- Telsa $1 - $9 per month
- Apple $1 - $9 per month
- Microsoft $1 - $9 per month
Deposit Method
- Wire Transfer
- Credit Cards
- Bank Account
Share
